PMID- 27289074
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20181202
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 144
DP  - 2016 Aug
TI  - High platelet reactivity on aspirin in patients with acute ST elevation 
      myocardial infarction.
PG  - 56-61
LID - S0049-3848(16)30330-9 [pii]
LID - 10.1016/j.thromres.2016.05.002 [doi]
AB  - BACKGROUND: Despite dual antiplatelet treatment, major ischemic events are common 
      following ST elevation myocardial infarction (STEMI). We aimed to assess high 
      platelet reactivity on aspirin (HPR-aspirin) and its association with P2Y12i 
      (HPR-P2Y12i) during the acute phase of STEMI. METHODS: We included all 
      consecutive patients admitted for STEMI treated by primary angioplasty in our 
      center for 1year. All patients received a loading dose followed by a maintenance 
      dose of aspirin (75mg/day) and prasugrel (ticagrelor or clopidogrel if 
      contraindicated). Platelet reactivity was assessed 4+/-1days and 75+/-15days after 
      admission using light transmission aggregometry with arachidonic acid 
      (LTA-AA-HPR-aspirin) and VASP (HPR-P2Y12i) to define HPR as well as serum 
      Thromboxane-B2 and LTA-ADP. Major cardiac and cerebrovascular events were 
      recorded for 1year. RESULTS: We included 106 patients - mean age was 61y.o., 76% 
      were male and 20% had diabetes. STEMI was anterior in 52% and LV ejection 
      fraction at discharge was 51+/-9%. 50% of patients were treated with prasugrel and 
      34% with ticagrelor. At day 4 after STEMI, HPR-aspirin was found in 26% patients 
      and HPR-P2Y12i in 7%. HPR- both aspirin and P2Y12i was found in 4%. Diabetes and 
      age were predictors of HPR-aspirin. HPR-aspirin was persistent 75days later in 
      36% patients. At 1year, 7.9% patients had experienced major adverse 
      cardiovascular and cerebrovascular events (MACCE). HPR-aspirin and HPR on both 
      aspirin and P2Y12i were significantly associated with MACCE. CONCLUSION: 
      HPR-aspirin is frequent just after STEMI and associated with MACCE especially 
      when associated with HPR-P2Y12i.
CI  - Copyright (c) 2016. Published by Elsevier Ltd.
FAU - Dillinger, Jean-Guillaume
AU  - Dillinger JG
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Saeed, Alaa
AU  - Saeed A
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Spagnoli, Vincent
AU  - Spagnoli V
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Sollier, Claire Bal Dit
AU  - Sollier CB
AD  - Department of Angio-hematology and IVS, Lariboisiere Hospital, AP-HP, Paris 
      Diderot University, Paris, France.
FAU - Sideris, Georgios
AU  - Sideris G
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Silberman, Stephane Manzo
AU  - Silberman SM
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Voicu, Sebastian
AU  - Voicu S
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France.
FAU - Drouet, Ludovic
AU  - Drouet L
AD  - Department of Angio-hematology and IVS, Lariboisiere Hospital, AP-HP, Paris 
      Diderot University, Paris, France.
FAU - Henry, Patrick
AU  - Henry P
AD  - Department of Cardiology, Lariboisiere Hospital, AP-HP, Paris Diderot University 
      - INSERM U 942, Paris, France. Electronic address: patrick.henry@lrb.aphp.fr.
LA  - eng
PT  - Journal Article
DEP - 20160510
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Disease
MH  - Adenosine/*analogs & derivatives/therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Blood Platelets/*drug effects/pathology
MH  - Brain Ischemia/etiology
MH  - Cardiovascular Diseases/etiology
MH  - Clopidogrel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Platelet Function Tests
MH  - Prasugrel Hydrochloride/*therapeutic use
MH  - Prospective Studies
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - ST Elevation Myocardial Infarction/blood/complications/*drug therapy/pathology
MH  - Survival Analysis
MH  - Ticagrelor
MH  - Ticlopidine/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Aspirin
OT  - Myocardial infarction
OT  - P2Y12 inhibitors
OT  - Platelet reactivity
EDAT- 2016/06/12 06:00
MHDA- 2017/04/14 06:00
CRDT- 2016/06/12 06:00
PHST- 2015/11/16 00:00 [received]
PHST- 2016/05/02 00:00 [revised]
PHST- 2016/05/04 00:00 [accepted]
PHST- 2016/06/12 06:00 [entrez]
PHST- 2016/06/12 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
AID - S0049-3848(16)30330-9 [pii]
AID - 10.1016/j.thromres.2016.05.002 [doi]
PST - ppublish
SO  - Thromb Res. 2016 Aug;144:56-61. doi: 10.1016/j.thromres.2016.05.002. Epub 2016 
      May 10.